ADHD Therapies Compared: What Does the Latest Meta-Analysis (2008-2023) Say?

A new systematic review and meta-analysis titled "Comparative Effectiveness of Pharmacological and Non-pharmacological Therapies for ADHD: A Systematic Review and Meta-analysis of Randomized Controlled Trials (2008-2023)" by Khan DI, Jameel S, Sabeeh, and Meraj H, published in Reviews on Recent Clinical Trials, takes a comprehensive look at the effectiveness of therapies for Attention-Deficit/Hyperactivity Disorder (ADHD). This study (PubMed ID: 41832627) analyzes randomized controlled trials (RCTs) from the last 15 years. But does it deliver on its promise? I'll take you on a detailed journey through its methodology, results, and weaknesses – and show you what this could mean for your daily life.

Cui Bono? The Trail of Money and Interests

First, the critical question: Who is behind this study? Unfortunately, the abstract provides no direct information on funding sources or conflicts of interest of the authors Khan DI, Jameel S, Sabeeh, and Meraj H. Nevertheless, caution is advised, as ADHD therapies – especially pharmacological approaches – are often supported by the pharmaceutical industry. Studies that portray medications positively could be influenced by such connections. Without transparency, a question mark remains: Who benefits from the results? I recommend always looking for funding sources in such analyses, as they can subtly guide design and interpretation.

The Methodological Gauntlet: The Study's Foundation

The meta-analysis is based on randomized controlled trials (RCTs) from 2008 to 2023, comparing pharmacological therapies (e.g., methylphenidate, atomoxetine) with non-pharmacological approaches (e.g., behavioral therapy, cognitive training programs). The study design – a systematic review with meta-analysis – is robust in principle, as it aggregates data from multiple RCTs, thereby increasing statistical power. However, it remains unclear how many studies were precisely included, as the abstract does not provide a specific number. Similarly, information on the total sample size is missing, which limits generalizability.

The study population presumably includes children and adults with an ADHD diagnosis, but without specific details on age, gender, or symptom severity, representativeness remains questionable. Measurement methods included standardized scales such as the ADHD-Rating Scale (ADHD-RS) for symptom assessment, but it is not mentioned whether these were obtained through self-report, parents, or clinicians – a potential bias. The duration of the included studies presumably varies, but without details, it remains open whether short-term or long-term effects were the focus. Control groups were used in the RCTs, but whether they were placebo groups or active comparison groups is unclear.

A central criti